Please check your internet connection and try again.
## Overview
Mylotarg (gemtuzumab ozogamicin) is a targeted cytotoxic therapy, an antibody-drug conjugate that targets the CD33 antigen found on the surface of myeloid leukemia cells. Upon binding to CD33, the drug is internalized, releasing a cytotoxic agent that induces DNA strand breaks and apoptosis.
## Primary Indications
* Newly diagnosed Acute Myeloid Leukemia (AML) in patients who are ineligible for intensive induction chemotherapy.
* Relapsed or refractory AML.
## Adult Dosing
**Newly Diagnosed AML (in combination with chemotherapy):**
* **Cycle 1:** 3 mg/m² on Day 1, Day 4, and Day 7.
* **Cycle 2 (if needed):** 3 mg/m² on Day 1.
**Relapsed or Refractory AML:**
* **First Relapse:** 3 mg/m² on Day 1, Day 4, and Day 7.
* **Subsequent Relapse:** 3 mg/m² on Day 1.
**Maximum cumulative dose:** 13.3 mg/m² over the course of treatment.
## Pediatric Dosing
Mylotarg is not approved for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** Dose reduction may be necessary. Consult specific guidelines or prescribing information for detailed recommendations. Generally, if bilirubin > 1.5 times the upper limit of normal (ULN), gemtuzumab ozogamicin should be avoided. If bilirubin is < 1.5 ULN, no dose adjustment is typically needed unless liver enzymes are significantly elevated.
* **Renal Impairment:** No specific dose adjustment is recommended for mild to moderate renal impairment. Use with caution in severe renal impairment.
* **Hematologic Toxicity:** Dose interruption or delay may be required based on blood counts and recovery.
* **Non-hematologic Toxicity:** Dose interruption or delay may be required based on severity and resolution of non-hematologic toxicities.
## Contraindications
* None specifically listed beyond hypersensitivity to gemtuzumab ozogamicin or excipients.
## Adverse Effects
* **Common:** Febrile neutropenia, nausea, vomiting, diarrhea, stomatitis, headache, fatigue, rash, hypokalemia, elevated liver enzymes (AST, ALT, bilirubin), thrombocytopenia, anemia, neutropenia.
* **Serious:** **Hepatotoxicity (Veno-occlusive disease/Sinusoidal Obstruction Syndrome - VOD/SOS)** is a significant concern, particularly when used in combination with other chemotherapy agents. Symptoms include hyperbilirubinemia, hepatomegaly, ascites, and weight gain. **Myelosuppression** (neutropenia, thrombocytopenia, anemia) is expected. **Hemorrhage**, **QT prolongation**, and **infusion-related reactions** can also occur.
## Key Drug Interactions
* **Chemotherapy Agents:** Increased risk of myelosuppression and hepatotoxicity when used in combination with other myelosuppressive or hepatotoxic agents.
* **Hepatotoxic Agents:** Concurrent use with other drugs known to cause liver injury should be avoided or carefully monitored.
* **Drugs Affecting QT Interval:** Use with caution due to the potential for QT prolongation.
## Monitoring
* **Hematologic parameters:** Complete blood counts (CBC) with differential and platelet counts prior to each dose and as clinically indicated.
* **Liver function tests:** LFTs (AST, ALT, bilirubin, alkaline phosphatase) prior to each dose and as clinically indicated. Monitor closely for signs and symptoms of VOD/SOS.
* **Renal function tests:** Serum creatinine.
* **Signs and symptoms of VOD/SOS:** Monitor for weight gain, ascites, jaundice, abdominal pain, and hepatomegaly.
* **Signs and symptoms of bleeding:** Monitor for bruising, petechiae, epistaxis, and gross bleeding.
* **Infusion-related reactions:** Monitor vital signs during and after infusion.
## Clinical Pearls
* Mylotarg carries a black box warning for hepatotoxicity, especially VOD/SOS, and myelosuppression.
* The risk of VOD/SOS is increased when gemtuzumab ozogamicin is administered with other chemotherapy agents, particularly in the first cycle.
* Close monitoring for hepatotoxicity, including VOD/SOS, is critical throughout treatment and after completion. Early recognition and management are key.
* Prehydration and antiemetic prophylaxis are recommended.
* The cumulative dose limit should not be exceeded due to increased risk of severe toxicity.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and local protocols for complete and up-to-date guidance.*
